Quest Partners LLC Buys 1,312 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Quest Partners LLC boosted its stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 21.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 7,458 shares of the company’s stock after acquiring an additional 1,312 shares during the period. Quest Partners LLC’s holdings in Nurix Therapeutics were worth $168,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in NRIX. Russell Investments Group Ltd. boosted its holdings in Nurix Therapeutics by 75.6% in the first quarter. Russell Investments Group Ltd. now owns 53,542 shares of the company’s stock valued at $787,000 after acquiring an additional 23,044 shares during the last quarter. Public Employees Retirement System of Ohio boosted its holdings in shares of Nurix Therapeutics by 3.7% during the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock worth $747,000 after buying an additional 1,820 shares in the last quarter. Opaleye Management Inc. bought a new position in shares of Nurix Therapeutics during the 1st quarter worth approximately $3,928,000. GAMMA Investing LLC boosted its holdings in shares of Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after buying an additional 3,424 shares in the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Nurix Therapeutics by 365.0% during the 2nd quarter. SG Americas Securities LLC now owns 103,199 shares of the company’s stock worth $2,154,000 after buying an additional 81,005 shares in the last quarter.

Insider Transactions at Nurix Therapeutics

In other news, CFO Houte Hans Van sold 3,546 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88. Following the completion of the transaction, the chief financial officer now owns 33,724 shares in the company, valued at approximately $818,818.72. This represents a 9.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christine Ring sold 3,290 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total value of $82,250.00. Following the transaction, the insider now owns 24,592 shares of the company’s stock, valued at $614,800. The trade was a 11.80 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 27,451 shares of company stock worth $663,160. 7.20% of the stock is owned by company insiders.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock opened at $21.23 on Thursday. Nurix Therapeutics, Inc. has a 1 year low of $5.68 and a 1 year high of $29.56. The firm has a market cap of $1.50 billion, a PE ratio of -7.30 and a beta of 2.20. The stock has a fifty day moving average price of $24.17 and a 200-day moving average price of $21.70.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million during the quarter, compared to analyst estimates of $13.85 million. As a group, equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on NRIX. Truist Financial began coverage on Nurix Therapeutics in a report on Wednesday, July 31st. They set a “buy” rating and a $36.00 price target on the stock. Royal Bank of Canada lowered their target price on Nurix Therapeutics from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. UBS Group began coverage on Nurix Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $35.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Nurix Therapeutics in a research report on Wednesday, November 6th. Finally, HC Wainwright increased their price target on Nurix Therapeutics from $26.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, October 21st. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat, Nurix Therapeutics has an average rating of “Moderate Buy” and an average target price of $29.40.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.